US20120077200A1 - Primers for diagnosing avellino corneal dystrophy - Google Patents
Primers for diagnosing avellino corneal dystrophy Download PDFInfo
- Publication number
- US20120077200A1 US20120077200A1 US13/264,784 US200913264784A US2012077200A1 US 20120077200 A1 US20120077200 A1 US 20120077200A1 US 200913264784 A US200913264784 A US 200913264784A US 2012077200 A1 US2012077200 A1 US 2012077200A1
- Authority
- US
- United States
- Prior art keywords
- seq
- nos
- corneal dystrophy
- avellino corneal
- real
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2561/00—Nucleic acid detection characterised by assay method
- C12Q2561/113—Real time assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to a real-time PCR primer pair and probe for diagnosing Avellino corneal dystrophy, and more particularly to such a real-time PCR primer pair and probe for diagnosing Avellino corneal dystrophy, which can accurately diagnose the presence or absence of a mutation in exon 4 of BIGH3 gene, which is responsible for Avellino corneal dystrophy.
- Corneal dystrophy is an autosomal dominant hereditary disease, which begins with a blurry symptom in the center of cornea and gradually spreads and thus ends up vision loss as a patient gets older. It includes Avellino corneal dystrophy, Granular corneal dystrophy, lattice type I corneal dystrophy, Reis-bucklers corneal dystrophy, etc., and is caused by mutation of a gene coding ⁇ IG-H3 protein.
- Avellino corneal dystrophy is a newly named disease in 1988, divided from generally called Granular corneal dystrophy because it was found to have discrete symptoms and genetic foundation. Also, it has been known to be the most common corneal dystrophy worldwide, 1/340 to 1/1000 of prevalence rate in Korea (the case of heterozygote) based on genetic analysis indicates that it is a common dystrophy (Holland, E. J. et al., Ophthalmology, 99:1564, 1992; Kennedy, S. M. et al., Br. J.
- the present inventors has found that if a patient suffering from heterozygous Avellino corneal dystrophy has LASIK surgery, 2 years later, opacity of cornea starts to develop aggressively and eventually results in vision loss (Jun, R. M. et al., Opthalmology, 111:463, 2004).
- eye surgery has been performed with an expectation that LASIK or Excimer Laser surgery would get rid of vision blurriness of a patient suffering from corneal dystrophy.
- approximately 3 hundred thousand cases of LASIK surgery have been performed, which leads to the assumption that 300 people lost their vision, based on 1/1000 of minimum estimation of heterozygous patients suffering from Avellino corneal dystrophy.
- Patients who have undergone LASIK surgery are mainly in their 20's and 30's carrying out productive activities; therefore, their vision loss causes serious troubles in both society and economics.
- Avellino corneal dystrophy is required to prevent the progression of Avellino corneal dystrophy by LASIK surgery
- diagnosis of Avellino corneal dystrophy is just conducted by microscopic observation of corneal opacity and thus often doctors miss latent symptoms of patients to perform LASIK surgery, which results in vision loss. Therefore, rapid and precise diagnosis of corneal dystrophy is urgent in need.
- the diagnosis of Avellino corneal dystrophy using said DNA chip disadvantageously require several steps, including a step of amplifying DNA in a sample, a step of hybridizing the amplified DNA with the DNA chip, a step of washing the hybridized DNA chip, and a step of detecting a positive response.
- the present inventors have made extensive efforts to develop a method capable of more efficiently diagnosing Avellino corneal dystrophy, and as a result, have found that, if the diagnosis of Avellino corneal dystrophy is performed using a pair of primers having nucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2 and probes having nucleotide sequences of SEQ ID NO: 13 and SEQ ID NO: 14 by a real-time PCR method, Avellino corneal dystrophy can be diagnosed in a more rapid and accurate manner than a conventional method, thereby completing the present invention.
- a main object of the present invention is to provide a primer pair and probe for more efficiently and accurately diagnosing Avellino corneal dystrophy using a real-time PCR method.
- the present invention provides a real-time PCR primer pair for diagnosing Avellino corneal dystrophy, which is represented by nucleotide sequences selected from the group consisting of SEQ ID NOs: 1 and 2, SEQ ID NOs: 3 and 4, SEQ ID NOs: 5 and 6, SEQ ID NOs: 7 and 8, SEQ ID NOs: 9 and 10, SEQ ID NOs: 11 and 12, SEQ ID NOs: 13 and 14, SEQ ID NOs: 15 and 16, SEQ ID NOs: 17 and 18, SEQ ID NOs: 19 and 20, SEQ ID NOs: 21 and 22, and SEQ ID NOs: 23 and 24.
- the present invention also provides a real-time PCR probe for diagnosing Avellino corneal dystrophy, which is represented by a nucleotide sequence selected from the group consisting of SEQ ID NO: 25 to SEQ ID NO: 42.
- FIG. 1 shows the results obtained from the design of real-time PCR primers and probes.
- “A” shows the results of real-time PCR carried out using optimal primers and probes
- “B” and “C” show the results of real-time PCR carried out using primers different from those in “A”.
- FIG. 2 shows the results of real-time PCR carried out using real-time PCR primers according to the present invention in order to detect a gene mutation causing Avellino corneal dystrophy.
- the present invention is directed to a real-time PCR primer pair for diagnosing Avellino corneal dystrophy, which is represented by nucleotide sequences selected from the group consisting of SEQ ID NOs: 1 and 2, SEQ ID NOs: 3 and 4, SEQ ID NOs: 5 and 6, SEQ ID NOs: 7 and 8, SEQ ID NOs: 9 and 10, SEQ ID NOs: 11 and 12, SEQ ID NOs: 13 and 14, SEQ ID NOs: 15 and 16, SEQ ID NOs: 17 and 18, SEQ ID NOs: 19 and 20, SEQ ID NOs: 21 and 22, and SEQ ID NOs: 23 and 24.
- Avellino corneal dystrophy is a disease caused by genetic abnormality in which the sequence CGC in exon 4 of BIGH3 gene is mutated to CAC so that arginine at residue of BIGH3 protein is mutated to histidine (R124H).
- Avellino corneal dystrophy can be diagnosed in a more rapid and accurate manner than a conventional method that uses a DNA chip.
- FIG. 1A shows the results of using well-designed primers and probes
- FIGS. 1B and 1C shows the results of using primers different from those used in FIG. 1A while using the same probes as those used in FIG. 1A .
- the design of the primers and the probes has a significant effect on reading.
- pairs of primers of SEQ ID NOs: 1 and 2, SEQ ID NOs: 3 and 4, SEQ ID NOs: 5 and 6, SEQ ID NOs: 7 and 8, SEQ ID NOs: 9 and 10, SEQ ID NOs: 11 and 12, SEQ ID NOs: 13 and 14, SEQ ID NOs: 15 and 16, SEQ ID NOs: 17 and 18, SEQ ID NOs: 19 and 20, SEQ ID NOs: 21 and 22 and SEQ ID NOs: 23 and 24 were designed, and real-time PCR was performed using each of the designed primer pairs. As a result, it was found that the use of the pair of primers of SEQ ID NOs: 1 and 2 showed the optimal results.
- the present invention is directed to a real-time PCR probe for diagnosing Avellino corneal dystrophy, which is represented by a nucleotide sequence selected from the group consisting of SEQ ID NO: 25 to SEQ ID NO: 42.
- probes of SEQ ID NOs: 25 to 42 were designed, and real-time PCR was performed each of the designed primers. As a result, it was found that the use of the probes of SEQ ID NOs: 13 and 14 showed the optimal results.
- ACD Fw primer (SEQ ID NO: 1) 5′-TCC ACC ACC ACT CAG CTG TA ACD Re primer: (SEQ ID NO: 2) 5′-CCA TCT CAG GCC TCA GCT T (60 bp) AV Fw primer: (SEQ ID NO: 3) 5′-TGC AGC CCT ACC ACT CTC AA AV Re primer: (SEQ ID NO: 4) 5′-AGG CCT CGT TGC TAG G (150 bp) Real Fw primer: (SEQ ID NO: 5) 5′-TAG TCT CTT ATT CTA ATA GA Real Re primer: (SEQ ID NO: 6) 5′-GCT GCA GAC TCT GTG TTT AA (860 bp) ACD Fw2 primer: (SEQ ID NO: 7) 5′-CCA TCC CTC CTT CTG TCT TCT G ACD Re2 primer: (SEQ ID NO: 8) 5′-CGG GCC CCT CCA TCT C (140
- probes of SEQ ID NOs: 25 to 42 were constructed.
- the probe binding to a normal gene fragment having no mutation was labeled with VIC, and the probe binding to a gene fragment having a mutation was labeled with FAM, and a minor groove binder (MGB) was attached to the probe so as to facilitate binding to a complementary gene fragment.
- VIC VIC
- FAM FAM
- MGB minor groove binder
- Normal probe 1 (SEQ ID NO: 25) VIC-CAC GGA CC G CAC GGA-NFQ (15 bp) Mutant probe 1: (SEQ ID NO: 26) FAM-CAC GGA CC A CAC GGA-NFQ Normal probe 2: (SEQ ID NO: 27) VIC-ACA CGG ACC G CA CG-NFQ Mutant probe 2: (SEQ ID NO: 28) FAM-ACA CGG ACC A CA CG-NFQ (14 bp) Normal probe 3: (SEQ ID NO: 29) VIC-TAC ACG GAC C G C A-NFQ Mutant probe 3: (SEQ ID NO: 30) FAM-TAC ACG GAC C A C A-NFQ (13 bp) Normal probe 4: (SEQ ID NO: 31) VIC-CTG TAC ACG GAC C G C ACG-NFQ Mutant probe 4: (SEQ ID NO: 32) FAM-CTG TAC ACG GAC C A C ACG-NFQ (18 bp
- Samples were taken from the blood, hair root and oral epithelial cells of test subjects, and DNA was isolated from the samples.
- the isolation and purification of DNA were performed using a partial modification of the phenol/chloroform extraction method (Miller, SA et al., Nucl. Acids Res. 16:1215, 1988), and the isolated DNA was dissolved in a suitable amount of TE buffer (10 mM Tris-Cl, 1 mM EDTA, pH7.4) and confirmed by electrophoresis on 1% agarose gel and used as template DNA in PCR.
- TE buffer 10 mM Tris-Cl, 1 mM EDTA, pH7.4
- the PCR reactions were performed using the primers (SEQ ID NOs: 1 to 12) for amplifying the fragment containing the mutation region, and the probes (SEQ ID NOs: 13 to 24), constructed in Example 1.
- the real-time PCR reaction was performed in the following conditions: 36 cycles each consisting of 10 min at 95° C., 15 sec at 92° C. and 1 min at 60° C., followed by a reaction for 5 min at 60° C.
- the use of the primer pair and probe according to the present invention can diagnose Avellino corneal dystrophy in a more rapid and accurate manner than a conventional method that uses a DNA chip or PCR.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a real-time PCR primer pair and probe for diagnosing Avellino corneal dystrophy, and more particularly to a real-time PCR primer pair and probe for diagnosing Avellino corneal dystrophy, which can accurately diagnose the presence or absence of a mutation in exon 4 of BIGH3 gene, which is responsible for Avellino corneal dystrophy. The use of the primer pair and probe according to the invention can diagnose Avellino corneal dystrophy in a more rapid and accurate manner than a conventional method that uses a DNA chip or PCR.
Description
- The present invention relates to a real-time PCR primer pair and probe for diagnosing Avellino corneal dystrophy, and more particularly to such a real-time PCR primer pair and probe for diagnosing Avellino corneal dystrophy, which can accurately diagnose the presence or absence of a mutation in exon 4 of BIGH3 gene, which is responsible for Avellino corneal dystrophy.
- Corneal dystrophy is an autosomal dominant hereditary disease, which begins with a blurry symptom in the center of cornea and gradually spreads and thus ends up vision loss as a patient gets older. It includes Avellino corneal dystrophy, Granular corneal dystrophy, lattice type I corneal dystrophy, Reis-bucklers corneal dystrophy, etc., and is caused by mutation of a gene coding βIG-H3 protein.
- Heterozygous patients suffering from Avellino corneal dystrophy appear to have severe loss of vision as getting older and homozygous patients appear to have complete loss of vision since 6 years old. Avellino corneal dystrophy is a newly named disease in 1988, divided from generally called Granular corneal dystrophy because it was found to have discrete symptoms and genetic foundation. Also, it has been known to be the most common corneal dystrophy worldwide, 1/340 to 1/1000 of prevalence rate in Korea (the case of heterozygote) based on genetic analysis indicates that it is a common dystrophy (Holland, E. J. et al., Ophthalmology, 99:1564, 1992; Kennedy, S. M. et al., Br. J. Ophthalmol., 80:489, 1996; Dolmetsch, A. M. et al., Can. J. Ophthalmol., 31:29, 1996; Afshari, N. A. et al., Arch. Ophthalmol., 119:16, 2001; Stewart, H. S. Hum. Mutat., 14:126, 1999).
- The present inventors has found that if a patient suffering from heterozygous Avellino corneal dystrophy has LASIK surgery, 2 years later, opacity of cornea starts to develop aggressively and eventually results in vision loss (Jun, R. M. et al., Opthalmology, 111:463, 2004). Previously, eye surgery has been performed with an expectation that LASIK or Excimer Laser surgery would get rid of vision blurriness of a patient suffering from corneal dystrophy. Also, even in Korea, approximately 3 hundred thousand cases of LASIK surgery have been performed, which leads to the assumption that 300 people lost their vision, based on 1/1000 of minimum estimation of heterozygous patients suffering from Avellino corneal dystrophy. Patients who have undergone LASIK surgery are mainly in their 20's and 30's carrying out productive activities; therefore, their vision loss causes serious troubles in both society and economics.
- In addition, after approval of LASIK surgery in year 2000 in USA, African American patients suffering from Avellino corneal dystrophy who underwent LASIK surgery have been found to lose eye sight, which infers that plenty of similar cases might be occurring throughout the world.
- Therefore, although accurate diagnosis of Avellino corneal dystrophy is required to prevent the progression of Avellino corneal dystrophy by LASIK surgery, the diagnosis of Avellino corneal dystrophy is just conducted by microscopic observation of corneal opacity and thus often doctors miss latent symptoms of patients to perform LASIK surgery, which results in vision loss. Therefore, rapid and precise diagnosis of corneal dystrophy is desperately in need.
- A DNA chip for detecting a mutation in BIGH3 gene, which is responsible for Avellino corneal dystrophy, was developed (Korean Patent Laid-Open Publication No. 10-2007-0076532). However, the diagnosis of Avellino corneal dystrophy using said DNA chip disadvantageously require several steps, including a step of amplifying DNA in a sample, a step of hybridizing the amplified DNA with the DNA chip, a step of washing the hybridized DNA chip, and a step of detecting a positive response.
- Accordingly, the present inventors have made extensive efforts to develop a method capable of more efficiently diagnosing Avellino corneal dystrophy, and as a result, have found that, if the diagnosis of Avellino corneal dystrophy is performed using a pair of primers having nucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2 and probes having nucleotide sequences of SEQ ID NO: 13 and SEQ ID NO: 14 by a real-time PCR method, Avellino corneal dystrophy can be diagnosed in a more rapid and accurate manner than a conventional method, thereby completing the present invention.
- A main object of the present invention is to provide a primer pair and probe for more efficiently and accurately diagnosing Avellino corneal dystrophy using a real-time PCR method.
- To achieve the above object, the present invention provides a real-time PCR primer pair for diagnosing Avellino corneal dystrophy, which is represented by nucleotide sequences selected from the group consisting of SEQ ID NOs: 1 and 2, SEQ ID NOs: 3 and 4, SEQ ID NOs: 5 and 6, SEQ ID NOs: 7 and 8, SEQ ID NOs: 9 and 10, SEQ ID NOs: 11 and 12, SEQ ID NOs: 13 and 14, SEQ ID NOs: 15 and 16, SEQ ID NOs: 17 and 18, SEQ ID NOs: 19 and 20, SEQ ID NOs: 21 and 22, and SEQ ID NOs: 23 and 24.
- The present invention also provides a real-time PCR probe for diagnosing Avellino corneal dystrophy, which is represented by a nucleotide sequence selected from the group consisting of SEQ ID NO: 25 to SEQ ID NO: 42.
-
FIG. 1 shows the results obtained from the design of real-time PCR primers and probes. InFIG. 1 , “A” shows the results of real-time PCR carried out using optimal primers and probes, “B” and “C” show the results of real-time PCR carried out using primers different from those in “A”. -
FIG. 2 shows the results of real-time PCR carried out using real-time PCR primers according to the present invention in order to detect a gene mutation causing Avellino corneal dystrophy. - In one aspect, the present invention is directed to a real-time PCR primer pair for diagnosing Avellino corneal dystrophy, which is represented by nucleotide sequences selected from the group consisting of SEQ ID NOs: 1 and 2, SEQ ID NOs: 3 and 4, SEQ ID NOs: 5 and 6, SEQ ID NOs: 7 and 8, SEQ ID NOs: 9 and 10, SEQ ID NOs: 11 and 12, SEQ ID NOs: 13 and 14, SEQ ID NOs: 15 and 16, SEQ ID NOs: 17 and 18, SEQ ID NOs: 19 and 20, SEQ ID NOs: 21 and 22, and SEQ ID NOs: 23 and 24.
- Avellino corneal dystrophy is a disease caused by genetic abnormality in which the sequence CGC in exon 4 of BIGH3 gene is mutated to CAC so that arginine at residue of BIGH3 protein is mutated to histidine (R124H).
- When a real-time PCR method is carried out using primers of the present invention, Avellino corneal dystrophy can be diagnosed in a more rapid and accurate manner than a conventional method that uses a DNA chip.
- In the real-time PCR method, it is very difficult to establish temperature conditions, because experiments using primers and probes should be carried out in the same temperature conditions. Particularly, if only one mutation position like Avellino corneal dystrophy is to be detected, primers and probes should be used in temperature conditions in which they can bind. Also, the probes can bind in a very limited temperature range from 1° C. and 3° C. in a state in which only one nucleotide differs between the probe for detecting a normal gene and the probe for detecting a mutant gene.
- Due to such conditions, it is important to find the same temperature conditions in which probes and primers can bind to a desired gene. Particularly, it is important to design a mutant probe and a normal probe such that the temperatures thereof can differ as much as possible within a limited range. In other words, the temperatures for primers and probes should be well consistent with each other, the temperature conditions for the forward primer and the reverse primer should be well consistent with each other, and the difference between the temperatures for the mutant probe and the normal probe should be able to be maximized.
FIG. 1A shows the results of using well-designed primers and probes, andFIGS. 1B and 1C shows the results of using primers different from those used inFIG. 1A while using the same probes as those used inFIG. 1A . As can be seen therein, the design of the primers and the probes has a significant effect on reading. - In the present invention, in order to construct optimal primers for diagnosing Avellino corneal dystrophy using a real-time PCR method, pairs of primers of SEQ ID NOs: 1 and 2, SEQ ID NOs: 3 and 4, SEQ ID NOs: 5 and 6, SEQ ID NOs: 7 and 8, SEQ ID NOs: 9 and 10, SEQ ID NOs: 11 and 12, SEQ ID NOs: 13 and 14, SEQ ID NOs: 15 and 16, SEQ ID NOs: 17 and 18, SEQ ID NOs: 19 and 20, SEQ ID NOs: 21 and 22 and SEQ ID NOs: 23 and 24 were designed, and real-time PCR was performed using each of the designed primer pairs. As a result, it was found that the use of the pair of primers of SEQ ID NOs: 1 and 2 showed the optimal results.
- In another aspect, the present invention is directed to a real-time PCR probe for diagnosing Avellino corneal dystrophy, which is represented by a nucleotide sequence selected from the group consisting of SEQ ID NO: 25 to SEQ ID NO: 42.
- In the present invention, in order to construct optimal probes for diagnosing Avellino corneal dystrophy using a real-time PCR method, probes of SEQ ID NOs: 25 to 42 were designed, and real-time PCR was performed each of the designed primers. As a result, it was found that the use of the probes of SEQ ID NOs: 13 and 14 showed the optimal results.
- Hereinafter, the present invention will be described in further detail with reference to examples. It will be obvious to a person having ordinary skill in the art that these examples are illustrative purposes only and are not to be construed to limit the scope of the present invention. That is, the following steps will be described as one illustrative ones and do not limit the scope of the present invention.
- In order to construct primers capable of amplifying a region comprising a mutation in exon 4 of BIGH3 gene, pairs of primers of SEQ ID NOs: 1 and 2, SEQ ID NOs: 3 and 4, SEQ ID NOs: 5 and 6, SEQ ID NOs: 7 and 8, SEQ ID NOs: 9 and 10, SEQ ID NOs: 11 and 12, SEQ ID NOs: 13 and 14, SEQ ID NOs: 15 and 16, SEQ ID NOs: 17 and 18, SEQ ID NOs: 19 and 20, SEQ ID NOs: 21 and 22 and SEQ ID NOs: 23 and 24 were designed using Primer Express 3.0 software (Applied Biosystems U.S.A).
-
ACD Fw primer: (SEQ ID NO: 1) 5′-TCC ACC ACC ACT CAG CTG TA ACD Re primer: (SEQ ID NO: 2) 5′-CCA TCT CAG GCC TCA GCT T (60 bp) AV Fw primer: (SEQ ID NO: 3) 5′-TGC AGC CCT ACC ACT CTC AA AV Re primer: (SEQ ID NO: 4) 5′-AGG CCT CGT TGC TAG G (150 bp) Real Fw primer: (SEQ ID NO: 5) 5′-TAG TCT CTT ATT CTA ATA GA Real Re primer: (SEQ ID NO: 6) 5′-GCT GCA GAC TCT GTG TTT AA (860 bp) ACD Fw2 primer: (SEQ ID NO: 7) 5′-CCA TCC CTC CTT CTG TCT TCT G ACD Re2 primer: (SEQ ID NO: 8) 5′-CGG GCC CCT CCA TCT C (140 bp) ACD Fw3 primer: (SEQ ID NO: 9) 5′-CAG AGA AGG GAG GGT GTG GTT ACD Re3 primer: (SEQ ID NO: 10) 5′-GGG CGA AGA TGG TGA AGC T (190 bp) ACD Fw4 primer: (SEQ ID NO: 11) 5′-TCC TCG TCC TCT CCA CCT GTA ACD Re4 primer: (SEQ ID NO: 12) 5′-AGC TGG CAA GGA GGC CC ACD Fw5 primer: (SEQ ID NO: 13) 5′-TTT GGG CTT TCC CAC ATG C ACD Re5 primer: (SEQ ID NO: 14) 5′-GGC AGA CGG AGG TCA TCT CA ACD Fw6 primer: (SEQ ID NO: 15) 5′-GTA GTA CCG TGC TCT CTG ACD Re6 primer: SEQ ID NO: 16) 5′-AGT TCC CCA TAA GAA TCC CCC ACD Fw7 primer: (SEQ ID NO: 17) 5′-GGC TGG ACC CCC AGA GG ACD Re7 primer: (SEQ ID NO: 18) 5′-ACC CCT CGG GGA AGT AAG G ACD Fw8 primer: (SEQ ID NO: 19) 5′-AAC CTT TAC GAG ACC CTG GGA ACD Re8 primer: (SEQ ID NO: 20) 5′-GAC TCC CAT CCA TCA TGC CC ACD Fw9 primer: (SEQ ID NO: 21) 5′-AGT CGT TGG ATC CAC CAC CA ACD Re9 primer: (SEQ ID NO: 22) 5′-GAC GTC ATT TCC TAC TGT TTC AGG ACD Fw10 primer: (SEQ ID NO: 23) 5′-CCC CCC AGA AAC AGC CTG ACD Re10 primer: (SEQ ID NO: 24) 5′-TTC TAA GGG GTT AAG GAG AAA GCT T - In order to detect a guanine-to-adenine mutation in exon 4 of BIGH3 gene, probes of SEQ ID NOs: 25 to 42 were constructed.
- The probe binding to a normal gene fragment having no mutation was labeled with VIC, and the probe binding to a gene fragment having a mutation was labeled with FAM, and a minor groove binder (MGB) was attached to the probe so as to facilitate binding to a complementary gene fragment.
-
Normal probe 1: (SEQ ID NO: 25) VIC-CAC GGA CCG CAC GGA-NFQ (15 bp) Mutant probe 1: (SEQ ID NO: 26) FAM-CAC GGA CCA CAC GGA-NFQ Normal probe 2: (SEQ ID NO: 27) VIC-ACA CGG ACC GCA CG-NFQ Mutant probe 2: (SEQ ID NO: 28) FAM-ACA CGG ACC ACA CG-NFQ (14 bp) Normal probe 3: (SEQ ID NO: 29) VIC-TAC ACG GAC CGC A-NFQ Mutant probe 3: (SEQ ID NO: 30) FAM-TAC ACG GAC CAC A-NFQ (13 bp) Normal probe 4: (SEQ ID NO: 31) VIC-CTG TAC ACG GAC CGC ACG-NFQ Mutant probe 4: (SEQ ID NO: 32) FAM-CTG TAC ACG GAC CAC ACG-NFQ (18 bp) Normal probe 5: (SEQ ID NO: 33) VIC-CTG TAC ACG GAC CGC ACG GAG-NFQ Mutant probe 5: (SEQ ID NO: 34) FAM-CTG TAC ACG GAC CAC ACG GAG-NFQ (21 bp) Normal probe 6: (SEQ ID NO: 35) VIC-GCT GTA CAC GGA CCG CAC GGA GAA-NFQ Mutant probe 6: (SEQ ID NO: 36) FAM-GCT GTA CAC GGA CCA CAC GGA GAA-NFQ Normal probe 7: (SEQ ID NO: 37) VIC-ACC GCA CGG AGA AGC-NFQ Mutant probe 7: (SEQ ID NO: 38) FAM-ACC ACA CGG AGA AGC-NFQ Normal probe 8: (SEQ ID NO: 39) VIC-ACC GCA CGG AGA AGC TGA GGC-NFQ Mutant probe 8: (SEQ ID NO: 40) FAM-ACC ACA CGG AGA AGC TGA GGC-NFQ Normal probe 8: (SEQ ID NO: 41) VIC-ACC GCA CGG AGA AGC TGA GGC CTG-NFQ Mutant probe 8: (SEQ ID NO: 42) FAM-ACC ACA CGG AGA AGC TGA GGC CTG-NFQ - Samples were taken from the blood, hair root and oral epithelial cells of test subjects, and DNA was isolated from the samples. The isolation and purification of DNA were performed using a partial modification of the phenol/chloroform extraction method (Miller, SA et al., Nucl. Acids Res. 16:1215, 1988), and the isolated DNA was dissolved in a suitable amount of TE buffer (10 mM Tris-Cl, 1 mM EDTA, pH7.4) and confirmed by electrophoresis on 1% agarose gel and used as template DNA in PCR.
- The PCR reactions were performed using the primers (SEQ ID NOs: 1 to 12) for amplifying the fragment containing the mutation region, and the probes (SEQ ID NOs: 13 to 24), constructed in Example 1.
- 25 μg of a master mix containing 10 pmol of each primer and 5 pmol of each probe was prepared and used in the PCR reaction.
- The real-time PCR reaction was performed in the following conditions: 36 cycles each consisting of 10 min at 95° C., 15 sec at 92° C. and 1 min at 60° C., followed by a reaction for 5 min at 60° C.
- After each cycle, fluorescence was measured. The sample positive to the VIC dye was diagnosed as having the normal gene, and the sample positive to the FAM gene was diagnosed as having the mutant gene.
- As a result, it could be seen that the use of the primer pair of SEQ ID NOs: 1 and 2 and the probes of SEQ ID NOs: 25 and 26 showed the most accurate and effective results (
FIG. 2 ). - Although the present invention has been described in detail with reference to the specific features, it will be apparent to those skilled in the art that this description is only for a preferred embodiment and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
- The use of the primer pair and probe according to the present invention can diagnose Avellino corneal dystrophy in a more rapid and accurate manner than a conventional method that uses a DNA chip or PCR.
Claims (3)
1. A real-time PCR primer pair for diagnosing Avellino corneal dystrophy, which is represented by nucleotide sequences selected from the group consisting of SEQ ID NOs: 1 and 2, SEQ ID NOs: 3 and 4, SEQ ID NOs: 5 and 6, SEQ ID NOs: 7 and 8, SEQ ID NOs: 9 and 10, SEQ ID NOs: 11 and 12, SEQ ID NOs: 13 and 14, SEQ ID NOs: 15 and 16, SEQ ID NOs: 17 and 18, SEQ ID NOs: 19 and 20, SEQ ID NOs: 21 and 22, and SEQ ID NOs: 23 and 24.
2. A real-time PCR probe for diagnosing Avellino corneal dystrophy, which is represented by a nucleotide sequence selected from the group consisting of SEQ ID NO: 25 to SEQ ID NO: 42.
3. The real-time PCR probe for diagnosing Avellino corneal dystrophy of claim 2 , wherein the real-time PCR probe is labeled with VIC or FAM.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0033528 | 2009-04-17 | ||
KR1020090033528A KR101251538B1 (en) | 2009-04-17 | 2009-04-17 | Primer for Avellino Corneal Dystrophy |
PCT/KR2009/007099 WO2010120027A1 (en) | 2009-04-17 | 2009-12-01 | Primer for detecting avellino corneal dystrophy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/007099 A-371-Of-International WO2010120027A1 (en) | 2009-04-17 | 2009-12-01 | Primer for detecting avellino corneal dystrophy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/454,669 Continuation US9938581B2 (en) | 2009-04-17 | 2014-08-07 | Primers for diagnosing Avellino corneal dystrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120077200A1 true US20120077200A1 (en) | 2012-03-29 |
Family
ID=42982670
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/264,784 Abandoned US20120077200A1 (en) | 2009-04-17 | 2009-12-01 | Primers for diagnosing avellino corneal dystrophy |
US14/454,669 Active 2029-12-20 US9938581B2 (en) | 2009-04-17 | 2014-08-07 | Primers for diagnosing Avellino corneal dystrophy |
US15/947,473 Active 2030-02-26 US11268146B2 (en) | 2009-04-17 | 2018-04-06 | Primers for diagnosing Avellino corneal dystrophy |
US17/584,701 Pending US20220205044A1 (en) | 2009-04-17 | 2022-01-26 | Primers for Diagnosing Avellino Corneal Dystrophy |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/454,669 Active 2029-12-20 US9938581B2 (en) | 2009-04-17 | 2014-08-07 | Primers for diagnosing Avellino corneal dystrophy |
US15/947,473 Active 2030-02-26 US11268146B2 (en) | 2009-04-17 | 2018-04-06 | Primers for diagnosing Avellino corneal dystrophy |
US17/584,701 Pending US20220205044A1 (en) | 2009-04-17 | 2022-01-26 | Primers for Diagnosing Avellino Corneal Dystrophy |
Country Status (13)
Country | Link |
---|---|
US (4) | US20120077200A1 (en) |
EP (2) | EP2420574B1 (en) |
JP (1) | JP5738842B2 (en) |
KR (1) | KR101251538B1 (en) |
CN (3) | CN110872613A (en) |
AU (1) | AU2009344501A1 (en) |
BR (1) | BRPI0924016A2 (en) |
CA (1) | CA2759222A1 (en) |
IL (1) | IL215845A0 (en) |
RU (1) | RU2534817C2 (en) |
SG (1) | SG175732A1 (en) |
WO (1) | WO2010120027A1 (en) |
ZA (1) | ZA201107967B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3068908A4 (en) * | 2013-11-15 | 2017-08-23 | Avellino Lab USA, Inc. | Methods for multiplex detection of alleles associated with ophthalmic conditions |
CN108085375A (en) * | 2016-11-07 | 2018-05-29 | 北京宏微特斯生物科技有限公司 | Detect the method and its kit of the genotype of corneal dystrophy gene polymorphism sites |
EP3486328A1 (en) | 2013-03-15 | 2019-05-22 | Avellino Lab USA, Inc. | Methods for improved isolation of genomic dna templates for allele detection |
US11987809B2 (en) | 2015-11-13 | 2024-05-21 | Avellino Lab Usa, Inc. | Methods for the treatment of corneal dystrophies |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101251538B1 (en) * | 2009-04-17 | 2013-04-08 | (주)아벨리노 | Primer for Avellino Corneal Dystrophy |
KR101125212B1 (en) * | 2010-10-01 | 2012-03-21 | (주)아벨리노 | System for diagnosis of avellino corneal dystrophy |
KR101480522B1 (en) | 2013-02-15 | 2015-01-08 | 솔젠트 (주) | Diagnostic Kit Useful for Allelic Discrimination of Avellino Corneal Dystrophy Genotype |
KR101577109B1 (en) * | 2013-04-23 | 2015-12-11 | 주식회사 녹십자엠에스 | Composition for diagnosing avellino corneal dystrophy and diagnostic method thereof |
CN106480200A (en) * | 2016-10-25 | 2017-03-08 | 北京亿昊基因技术有限公司 | A kind of detection method with corneal dystrophy associated gene mutation site rapidly and efficiently |
KR101957919B1 (en) * | 2017-01-02 | 2019-03-13 | 부산대학교 산학협력단 | Biosensors for Diagnosing Corneal Dystrophies and Uses Thereof |
KR20200129539A (en) | 2019-05-09 | 2020-11-18 | 주식회사 왓슨알앤디 | Detection Method of Corneal Dystrophies using Polymerase Chain Reaction and Restriction Enzyme Digestion |
KR102249878B1 (en) * | 2019-09-24 | 2021-05-11 | 주식회사 에이엠에스바이오 | A Composition for Diagnosing Granular Corneal Dystrophy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007083928A1 (en) * | 2006-01-18 | 2007-07-26 | Medigenes Co., Ltd | Dna chip for diagnosis of corneal dystrophy |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6018713A (en) | 1997-04-09 | 2000-01-25 | Coli; Robert D. | Integrated system and method for ordering and cumulative results reporting of medical tests |
JP3380744B2 (en) | 1998-05-19 | 2003-02-24 | 株式会社日立製作所 | Sensor and measuring device using the same |
US6171112B1 (en) | 1998-09-18 | 2001-01-09 | Wyngate, Inc. | Methods and apparatus for authenticating informed consent |
AU4135600A (en) | 1999-03-29 | 2000-10-16 | Genset | Prostate cancer associated human fibronectin gene and biallelic markers |
ATE381626T1 (en) | 2000-04-13 | 2008-01-15 | Univ Georgetown | GENETIC DIAGNOSIS TO DETERMINE QT PROLONGATION AS AN ADVERSE REACTION TO DRUGS |
US8438042B2 (en) | 2002-04-25 | 2013-05-07 | National Biomedical Research Foundation | Instruments and methods for obtaining informed consent to genetic tests |
EP1551972A4 (en) | 2001-08-09 | 2005-08-31 | Curagen Corp | Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
EP1451558A1 (en) | 2001-11-28 | 2004-09-01 | Graffinity Pharmaceuticals Aktiengesellschaft | Surface plasmon resonance (spr) sensor surface support |
US20030211141A1 (en) * | 2001-12-11 | 2003-11-13 | Lebaron Richard G. | Genetic and protein manipulation of betaIG-H3 for the treatment and cure of muscular dystrophies |
US6943417B2 (en) | 2003-05-01 | 2005-09-13 | Clemson University | DNA-based memory device and method of reading and writing same |
US20050019757A1 (en) | 2003-06-12 | 2005-01-27 | Stolarchuk Danylo J. | Contaminant detection apparatus |
WO2005015198A1 (en) | 2003-08-06 | 2005-02-17 | Nippon Telegraph And Telephone Corporation | Molecule detection method using porous material, the porous material, and manufacturing method for the porous material |
US20070212542A1 (en) | 2003-10-22 | 2007-09-13 | The Regents Of The University Of California | Methods for Preparing and Functionalizing Nanoparticles |
WO2005047534A2 (en) | 2003-10-28 | 2005-05-26 | Bayer Healthcare Ag | Methods and compositions for the response prediction of malig-nant neoplasia to treatment |
EP1541528A1 (en) | 2003-12-08 | 2005-06-15 | Institut Jozef Stefan | Quasi-one-dimensional polymers based on the metal-chalcogen-halogen system |
US20060057604A1 (en) | 2004-03-15 | 2006-03-16 | Thinkfar Nanotechnology Corporation | Method for electrically detecting oligo-nucleotides with nano-particles |
AU2005246415B8 (en) | 2004-05-19 | 2011-09-01 | Vp Holding, Llc | Optical sensor with layered plasmon structure for enhanced detection of chemical groups by SERS |
US7713849B2 (en) | 2004-08-20 | 2010-05-11 | Illuminex Corporation | Metallic nanowire arrays and methods for making and using same |
US7332329B2 (en) | 2004-09-24 | 2008-02-19 | Wisconsin Alumni Research Foundation | Versatile substrate for SPR detection |
US20080267946A1 (en) * | 2005-03-08 | 2008-10-30 | Medigenes Co., Ltd | Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising an Antibody Against Tgf-Beta |
JP2006250668A (en) | 2005-03-10 | 2006-09-21 | Tatsuro Endo | Non-labelled biochip |
EP1715326A1 (en) | 2005-04-22 | 2006-10-25 | Universität Heidelberg | Sensor chip with connected non-metallic particles comprising a metallic coating |
US20070154903A1 (en) | 2005-06-23 | 2007-07-05 | Nanosphere, Inc. | Selective isolation and concentration of nucleic acids from complex samples |
CN101374850A (en) * | 2006-01-18 | 2009-02-25 | 株式会社美迪基尼斯 | DNA chip for diagnosis of corneal dystrophy |
BRPI0708853A2 (en) | 2006-03-21 | 2011-07-19 | Univ Washington State Res Fdn | genetic polymorphisms in the corticotropin-releasing hormone (crh) gene as markers to improve meat fat streak pattern score and / or subcutaneous fat depth |
RU2348695C2 (en) * | 2006-05-23 | 2009-03-10 | Закрытое акционерное общество "Молекулярно-медицинские технологии" | Differentiating and specific oligonucleotids for dna sequence identification for infection agents in biological materials, method of species identification of infection agents, biochip and method implementation kit |
EP1932922A1 (en) | 2006-12-13 | 2008-06-18 | Desitin Arzneimittel GmbH | In situ hybridisation detection of DNA squences |
EP2115123A4 (en) | 2007-01-16 | 2010-07-07 | Applied Biosystems Llc | Selective lysis of sperm cells |
US7898658B2 (en) | 2007-01-23 | 2011-03-01 | The Regents Of The University Of California | Platform for chemical and biological sensing by surface-enhanced Raman spectroscopy |
KR100891096B1 (en) | 2007-02-13 | 2009-03-31 | 삼성전자주식회사 | Oligomer probe array and method of fabricating the same |
JP5222599B2 (en) | 2007-07-20 | 2013-06-26 | 株式会社日立ハイテクノロジーズ | Nucleic acid analysis device and nucleic acid analysis apparatus using the same |
CN101144812B (en) | 2007-10-17 | 2012-02-22 | 中国科学院光电技术研究所 | Localized surface plasma biochemical sensor production method |
US20120231537A1 (en) | 2008-04-30 | 2012-09-13 | Gradalis, Inc. | Highly Pure Plasmid DNA Preparations |
KR101251538B1 (en) * | 2009-04-17 | 2013-04-08 | (주)아벨리노 | Primer for Avellino Corneal Dystrophy |
US8865402B2 (en) | 2009-08-26 | 2014-10-21 | Clemson University Research Foundation | Nanostructured substrates for surface enhanced raman spectroscopy (SERS) and detection of biological and chemical analytes by electrical double layer (EDL) capacitance |
KR101125212B1 (en) * | 2010-10-01 | 2012-03-21 | (주)아벨리노 | System for diagnosis of avellino corneal dystrophy |
TWI812047B (en) | 2013-11-15 | 2023-08-11 | 美商阿韋利諾美國實驗有限公司 | Methods for multiplex detection of alleles associated with ophthalmic conditions |
-
2009
- 2009-04-17 KR KR1020090033528A patent/KR101251538B1/en active IP Right Grant
- 2009-12-01 AU AU2009344501A patent/AU2009344501A1/en not_active Abandoned
- 2009-12-01 JP JP2012505796A patent/JP5738842B2/en active Active
- 2009-12-01 CN CN201910865016.1A patent/CN110872613A/en active Pending
- 2009-12-01 EP EP09843403.8A patent/EP2420574B1/en active Active
- 2009-12-01 BR BRPI0924016A patent/BRPI0924016A2/en not_active Application Discontinuation
- 2009-12-01 CA CA2759222A patent/CA2759222A1/en not_active Abandoned
- 2009-12-01 SG SG2011075728A patent/SG175732A1/en unknown
- 2009-12-01 CN CN201510121642.1A patent/CN104774930A/en active Pending
- 2009-12-01 WO PCT/KR2009/007099 patent/WO2010120027A1/en active Application Filing
- 2009-12-01 RU RU2011146553/10A patent/RU2534817C2/en active
- 2009-12-01 EP EP14186678.0A patent/EP2848689A1/en not_active Withdrawn
- 2009-12-01 CN CN200980159748.3A patent/CN102459593B/en active Active
- 2009-12-01 US US13/264,784 patent/US20120077200A1/en not_active Abandoned
-
2011
- 2011-10-14 ZA ZA2011/07967A patent/ZA201107967B/en unknown
- 2011-10-23 IL IL215845A patent/IL215845A0/en unknown
-
2014
- 2014-08-07 US US14/454,669 patent/US9938581B2/en active Active
-
2018
- 2018-04-06 US US15/947,473 patent/US11268146B2/en active Active
-
2022
- 2022-01-26 US US17/584,701 patent/US20220205044A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007083928A1 (en) * | 2006-01-18 | 2007-07-26 | Medigenes Co., Ltd | Dna chip for diagnosis of corneal dystrophy |
Non-Patent Citations (3)
Title |
---|
GenBank Accession No. AF035627 [retrieved on-line: http://www.ncbi.nlm.nih.gov/nuccore/AF035627.1, retrieval date, 9/7/2013], published date December 1997, Skonier et al. * |
Grove, D.S., "Quantitative Real-Time Polymerase Chain Reaction for the Core Facility Using TaqMan and the Perkin-Elmer/Applied Biosystems Division 7700 Sequence Detector," Journal of Biomolecular Techniques, 1999, vol. 10, pages 11-16. * |
Huerva et al., "Role of BIGH3 R124H mutation in the diagnosis of Avellino corneal dystrophy," European Journal of Ophthalmology, May 2008, vol. 18, no. 3, pages 345-350. * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3486328A1 (en) | 2013-03-15 | 2019-05-22 | Avellino Lab USA, Inc. | Methods for improved isolation of genomic dna templates for allele detection |
EP3825413A1 (en) | 2013-03-15 | 2021-05-26 | Avellino Lab USA, Inc. | Methods for improved isolation of genomic dna templates for allele detection |
EP3068908A4 (en) * | 2013-11-15 | 2017-08-23 | Avellino Lab USA, Inc. | Methods for multiplex detection of alleles associated with ophthalmic conditions |
AU2014348279B2 (en) * | 2013-11-15 | 2021-02-18 | Avellino Lab Usa, Inc. | Methods for multiplex detection of alleles associated with ophthalmic conditions |
EP3872192A1 (en) | 2013-11-15 | 2021-09-01 | Avellino Lab USA, Inc. | Methods for multiplex detection of alleles associated with ophthalmic conditions |
US11525160B2 (en) | 2013-11-15 | 2022-12-13 | Avellino Lab Usa, Inc. | Methods for multiplex detection of alleles associated with ophthalmic conditions |
US11987809B2 (en) | 2015-11-13 | 2024-05-21 | Avellino Lab Usa, Inc. | Methods for the treatment of corneal dystrophies |
CN108085375A (en) * | 2016-11-07 | 2018-05-29 | 北京宏微特斯生物科技有限公司 | Detect the method and its kit of the genotype of corneal dystrophy gene polymorphism sites |
Also Published As
Publication number | Publication date |
---|---|
US20220205044A1 (en) | 2022-06-30 |
ZA201107967B (en) | 2013-08-28 |
JP2012523831A (en) | 2012-10-11 |
EP2420574A1 (en) | 2012-02-22 |
CA2759222A1 (en) | 2010-10-21 |
CN102459593A (en) | 2012-05-16 |
US9938581B2 (en) | 2018-04-10 |
JP5738842B2 (en) | 2015-06-24 |
KR20100115030A (en) | 2010-10-27 |
EP2420574B1 (en) | 2014-10-29 |
CN110872613A (en) | 2020-03-10 |
CN104774930A (en) | 2015-07-15 |
BRPI0924016A2 (en) | 2016-10-11 |
RU2011146553A (en) | 2013-05-27 |
KR101251538B1 (en) | 2013-04-08 |
US20180274034A1 (en) | 2018-09-27 |
AU2009344501A1 (en) | 2011-11-17 |
US20150093751A1 (en) | 2015-04-02 |
RU2534817C2 (en) | 2014-12-10 |
WO2010120027A1 (en) | 2010-10-21 |
US11268146B2 (en) | 2022-03-08 |
SG175732A1 (en) | 2011-12-29 |
IL215845A0 (en) | 2012-01-31 |
EP2420574A4 (en) | 2012-08-29 |
CN102459593B (en) | 2015-04-08 |
EP2848689A1 (en) | 2015-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220205044A1 (en) | Primers for Diagnosing Avellino Corneal Dystrophy | |
US8182990B2 (en) | Method for diagnosing or predicting susceptibility to optic neuropathy | |
US20140170657A1 (en) | Probe for Detection of Polymorphism in EGFR Gene, Amplification Primer, and Use Thereof | |
US20120231463A1 (en) | Primer Set for Amplification of MTHFR Gene, MTHFR Gene Amplification Reagent Containing the Same, and Use of the Same | |
US20210115499A1 (en) | Methods for Improved Isolation of Genomic DNA Templates for Allele Detection | |
US9856516B2 (en) | Methods for improved isolation of genomic DNA templates for allele detection | |
US20120252024A1 (en) | Probe for Detection of Polymorphism in C-Kit Gene and Use Thereof | |
KR101231899B1 (en) | Primer for Avellino Corneal Dystrophy | |
TW201311908A (en) | Method and kit for diagnosis of canine glaucoma | |
KR101231903B1 (en) | Primer for Avellino Corneal Dystrophy | |
KR101231902B1 (en) | Primer for Avellino Corneal Dystrophy | |
KR101231901B1 (en) | Primer for Avellino Corneal Dystrophy | |
KR101231900B1 (en) | Primer for Avellino Corneal Dystrophy | |
KR20160088028A (en) | Method and kit for monitoring TGFBI-linked corneal dystrophy | |
JP2002306165A (en) | Gene related with open-angle glaucoma including normal tension glaucoma | |
DE60308665T2 (en) | GENERATION PROCEDURE FOR ASSESSING THE RISK OF GLOBALIZATION | |
JP5594655B2 (en) | Method for determining causal mutation of retinitis pigmentosa and oligonucleotide used therefor | |
KR20210035934A (en) | A Composition for Diagnosing Granular Corneal Dystrophy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AVELLINO CO., LTD., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, GENE;YUN, JUNG KUK;SIGNING DATES FROM 20111114 TO 20111116;REEL/FRAME:027338/0244 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |